BeiGene, Ltd. (NASDAQ: ONC) — Company Overview, News & Financial Data
BeiGene, Ltd.
ONC BeiGene, Ltd.
Company profile
BeiGene, Ltd.
BeiGene, Ltd. is a global biotechnology company focused on discovering, developing, manufacturing, and commercializing targeted therapies and immunotherapies for cancer treatment. The company advances a broad clinical pipeline of small molecule inhibitors, monoclonal antibodies, and bispecific antibodies aimed at addressing hematologic malignancies and solid tumors worldwide. Operating across North America, Europe, Asia-Pacific, and other international regions, the organization conducts research, clinical trials, and commercial operations to improve therapeutic access and outcomes for oncology patients.
Snapshot
Public USOwnership
2010Year founded
~12,000Employees
Basel, SwitzerlandHead office
Loading Map...
Global footprint
Operations
Products and/or services of BeiGene, Ltd.
- Bruton Tyrosine Kinase Inhibitors: Small molecule kinase inhibitors designed to block signals required for B-cell proliferation and survival, indicated for treating chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, and Waldenstrom macroglobulinemia globally.
- PD-1 Immune Checkpoint Inhibitors: Humanized IgG4 monoclonal antibodies directed against programmed cell death protein 1, developed to restore anti-tumor immune response in esophageal, gastric, and non-small cell lung cancers across international markets.
- HER2 Bispecific Antibodies: Dual HER2-targeted bispecific antibodies engineered to bind distinct domains of the HER2 receptor, inhibiting cell signaling and mediating tumor cell death in HER2-expressing gastrointestinal and biliary tract cancers.
- Chimeric Degradation Activating Compounds: Targeted protein degradation platform therapies engineered to selectively destroy disease-causing target proteins, including novel next-generation BTK degraders for hematologic malignancies resistant to standard targeted inhibitor treatments.
- Antibody-Drug Conjugates: Monoclonal antibodies chemically conjugated to potent cytotoxic payloads designed to selectively deliver therapeutic agents directly to target tumor cells expressing specific surface antigens across thoracic, gynecological, and gastrointestinal cancers.
- Biopharmaceutical Manufacturing and Supply: Global commercial and clinical-scale production operations encompassing small-molecule chemical synthesis, large-molecule biologics manufacturing, secondary packaging, and supply chain management across specialized facilities in North America, Europe, and Asia.
BeiGene, Ltd. executive team
- John V. OylerCo-Founder, Executive Chairman & CEO
- Wang LaiPresident and Global Head of Research & Development
- Xiaodong WangCo-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder
- Aaron RosenbergChief Financial Officer
- Chan LeeGeneral Counsel, Senior VP & Corporate Secretary
- Titus B. BallVP & Chief Accounting Officer
- Marcello DamianiChief Technology Officer
- Liza HeapesHead of Investor Relations
- Eleanor DuffSenior VP & Head of Corporate Communications
- Graham HardimanGlobal Head of Human Resources
Latest news about BeiGene, Ltd.
BeOne announces 4 cancer programs for ESMO 2026
United StatesBeOne ZIIHERA trial shows survival improvement
United StatesBeOne wins FDA approval for TEVIMBRA GEA treatment
United StatesBeOne and Revolution Medicines expand oncology partnership
United StatesBeOne Medicines revenue jumps 30% to $1.7 billion
United StatesBeOne Medicines reports positive phase 3 data for Brukinsa plus rituximab in MCL
United States
Key financials
Reported results for BeiGene, Ltd., in USD.
- Market cap
- 41.6B
- Revenue (TTM)
- 6.1B
- P/E ratio
- 65.5
- EPS (diluted, TTM)
- 5.6
- Dividend yield
- —
- Profit margin
- 10.7%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 5.3B | 447.1M | 286.9M | |
| 3.8B | -568.2M | -644.8M | |
| 2.5B | -1.2B | -881.7M | |
| 1.4B | -1.8B | -2B |